Lung Cancer, Multiple Primary Lung Cancers, Non Small Cell Lung Cancer
Conditions
Keywords
multiple primary lung cancer, ctDNA, evolution, tumor heterogeneity, microenvironment
Brief summary
To investigate the evolutionary genomic landscape, explore the genetic tumor heterogeneity and microenvironment of multiple primary lung cancer (MPLC) by using tissue genetic analysis and circulating tumor DNA detection, in order to provide robust evidence for the diagnosis, treatment, and surveillance of MPLC.
Detailed description
Multiple primary lung cancer (MPLC) has become a worldwide problem due to the difficulty in diagnosis, treatment and surveillance. Although exploring tumour clonal heterogeneity and microenvironment can help understand cancer evolution and impact therapeutic outcome, study is still lacking in this field on MPLC. Circulating tumor DNA (ctDNA) are short DNA fragments, which can be obtained conveniently and non-invasively, providing comprehensive views of the tumor as were shed by tumor cells from multiple tumor regions. Therefore, we design a prospective study of patients with surgically treated MPLC, aiming to use ctDNA technique to define the evolutionary landscape of MPLC through inter-tumor and intra-tumor heterogeneity by multi-region sampling and genetic analysis. We will also explore the the microenvironment by RNA sequencing and T cell receptor sequencing. This study may help understand the genetic evolution and microenvironment of MPLC, and provide evidence for the diagnosis, treatment and surveillance of these patients.
Interventions
None listed
Sponsors
Guangzhou Burning Rock Medical Examination Institute Co., Ltd.
Peking University People's Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Aged 18 to 80 years 1. Patients who are clinically diagnosed multiple lung cancers, and undergo surgical treatment. 2. No history of any malignancy in recent 5 years. 3. No chemotherapy, radiotherapy or targeted therapy will be performed before surgery. 4. Surgical removal of at least 2 tumors confirmed to be lung cancer postoperatively by pathologic evaluation.
Exclusion criteria
1. All lesions present as pure ground-glass opacities (GGOs) on CT scans. 2. Patients who do not undergo R0 resection (including tumors located bilaterally but only unilaterally resected). 3. Unqualified blood samples. 4. Unable to comply with the study procedure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor heterogeneity of multiple primary lung cancer | 3 year | Explore the intra-tumor and inter-tumor genetic heterogeneity by analysis of clonal and subclonal mutations detected by ctDNA. |
| Microenvironment of multiple primary lung cancer | 3 year | Using RNA sequencing and T cell receptor (TCR) sequencing to evaluate the microenvironment of each lesion of multiple primary lung cancer, including T cell receptpr clonality ,diversity , evenness, and richness. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between ctDNA and clonal variation | 3 year | Explore the correlation between the detection rate of ctDNA and subclonal mutations of different tumor sites detected by genetic analysis. |
| Correlation between ctDNA and tumor burden | 3 year | Explore the correlation between the detection rate of ctDNA and tumor burden. |
Contacts
Primary ContactKezhong Chen, M.D.
Outcome results
None listed